Emtricitabine/tenofovir or abacavir/lamivudine — Competitive Intelligence Brief

Emtricitabine/tenofovir or abacavir/lamivudine (Emtricitabine/tenofovir or abacavir/lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Emtricitabine/tenofovir or abacavir/lamivudine (Emtricitabine/tenofovir or abacavir/lamivudine) — Fundacion SEIMC-GESIDA. These are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral RNA from being converted into DNA and integrated into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Emtricitabine/tenofovir or abacavir/lamivudine TARGET	Emtricitabine/tenofovir or abacavir/lamivudine	Fundacion SEIMC-GESIDA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
Antiretroviral therapy plus Interleukin-2	Antiretroviral therapy plus Interleukin-2	Juan A. Arnaiz	marketed	Combination immunotherapy and antiviral	HIV reverse transcriptase, protease, integrase (ART component); IL-2 receptor (IL-2 component)
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) class)

1. Fundacion SEIMC-GESIDA · 1 drug in this class